Stereotaxis has announced a global collaboration with Abbott to integrate Abbott’s EnSite X EP system with Stereotaxis’ Robotic Magnetic Navigation system.
The combination of Abbott’s cardiac mapping system with Stereotaxis’ advanced robotic technology brings together highly detailed real-time diagnostic information with the unprecedented precision and stability of robotics during therapy delivery, Stereotaxis said in a press release.
Stereotaxis and Abbott have successfully completed integration of their technologies and performed testing demonstrating joint compatibility. The integrated technologies are cleared for use in Europe with additional regulatory clearances expected in the coming months.
“The combination of these two technologies is a seminal event for the community of physicians who have pioneered and championed robotics in electrophysiology,” said J Peter Weiss (Banner University of Arizona Medical Center, Tucson, USA). “Joint use of EnSite X with Robotic Magnetic Navigation is beneficial for the broad spectrum of cardiac ablation procedures and is most impactful in treating complex and challenging cardiac arrhythmias.”
Abbott’s EnSite X system US Food and Drug Admnistration (FDA) clearance in 2021.
“Stereotaxis is delighted to collaborate with Abbott and to be able to share this significant milestone for the electrophysiology field,” said David Fischel, chairman and CEO of Stereotaxis. “This collaboration further reinforces our commitment to meaningful innovations that advance the frontiers of medical progress. It provides additional choice for the community of robotic users and ensures patients, physicians and providers can benefit from the combination of the finest diagnostic and therapeutic technologies.”
